4 Yrs

Mylan Technologies Inc.

110 Lake Street
St. Albans, Vermont-05478, USA+(1)-(800)-5325226
Contact Supplier
Yes! I am interested
FOB Price : Get Latest Price

somerset pharmaceuticals, inc. , a wholly owned subsidiary of mylan inc. ,
received approval from the fda for emsam® transdermal
selegiline, on february 27 of 2006. Emsam® is the
first transdermal treatment for major depressive disorder. All aspects of the
emsam® product related to its design, chemistry,
manufacturing and controls were the result of the integration of the talents
and expertise of mti scientists. Emsam® is
manufactured by mti.

antidepressants increased the risk of suicidal thinking and behavior
(suicidality) in short-term studies in children and adolescents with major
depressive disorder (mdd) and other psychotic disorders. Anyone considering the
use of emsam® or other antidepressants in a child or
adolescent must balance this risk with the clinical need.

emsam® is not indicated for use in pediatric patients.

for additional details please see full prescribing information, including boxed

  • Molecular formula:HNO3 Molecular weight:63.01 CAS NO.:7697-37-2 Property:Pure nitric acid is colorless liquid with pungent odor,it's density is ...

    view details
  • The E.L.I.T.E. Series, designed for detection and identification of trace explosives and explosives precursors, is field-proven and currently in use ...

    view details
  • featuresn-acetyl cysteine (nac) 500 mg capsules contain a highly stable form of cysteine, an important sulfur-containing amino acid. the ...

    view details
More Products From This Supplier
Recommended Catalog

Isosorbide dinitrate Synonym: ...

view details
sending enquiry ....
Thank You

unable to instantiate your call right now. please try after some time.


© Copyright